{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T10:34:49Z","timestamp":1764153289945,"version":"3.46.0"},"reference-count":13,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Clomipramine, a Tricyclic Antidepressant (TCA), is known for its efficacy in treating Obsessive-compulsive Disorder (OCD). However, it is associated with several side\neffects, including urinary retention. This case report discusses the case of a 20-year-old male with\nOCD who developed urinary retention following clomipramine administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Representation:<\/jats:title>\n                    <jats:p>A 20-year-old male with a one-year history of OCD with psychotic features\nwas admitted to SIR-T Hospital, Bhavnagar, due to worsening symptoms. He was prescribed\nclomipramine along with other psychotropic medications. On the 16th day of hospitalization, the\npatient experienced acute urinary retention, necessitating catheterization. Clomipramine dosage\nwas subsequently reduced, resulting in the resolution of urinary retention. The patient was\ndischarged after 29 days with no further urinary complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>The causality assessment suggested a probable link between clomipramine and urinary retention, supported by the Naranjo Scale, WHO-UMC criteria, and literature. The anticholinergic properties of clomipramine likely contributed to the condition. Despite its side effects,\nclomipramine remains a valuable treatment for OCD, requiring careful dose management to mitigate adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Clinicians should be vigilant for urinary retention in patients receiving\nclomipramine, especially at higher doses. Regular monitoring and dose adjustments are crucial for\nmanaging this side effect without compromising the therapeutic benefits for OCD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115748863337946250101110356","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T06:10:49Z","timestamp":1738131049000},"page":"501-503","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clomipramine-Induced Urinary Retention in an Adult Male - A Case Report"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0578-468X","authenticated-orcid":true,"given":"Priya","family":"Mehta","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Government Medical College, Bhavnagar, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Sapovadia","sequence":"additional","affiliation":[{"name":"Department of Psychiatry,Government Medical College, Bhavnagar, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhargav","family":"Purohit","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Government Medical College, Bhavnagar, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"1795","volume":"347","author":"Martin J.","year":"2019","unstructured":"Martin J.; Investigating chronic urinary retention. BMJ  2019,347,1795-1797","journal-title":"BMJ"},{"key":"ref=2","author":"Dougherty JM.","year":"2020","unstructured":"Dougherty JM.; Male urinary retention. StatPearls  2020","journal-title":"StatPearls"},{"key":"ref=3","author":"Ghossein N.","year":"2023","unstructured":"Ghossein N.; Anticholinergic medications. StatPearls  2023","journal-title":"StatPearls"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2165\/00002018-200831050-00002","volume":"31","author":"Verhamme K.M.C.","year":"2008","unstructured":"Verhamme K.M.C.; Sturkenboom M.C.J.M.; Stricker B.H.C.; Bosch R.; Drug-induced urinary retention: Incidence, management and prevention. Drug Saf  2008,31(5),373-388","journal-title":"Drug Saf"},{"key":"ref=5","first-page":"838","author":"Wexler P.","year":"2014","unstructured":"Wexler P.;  ScienceDirect  2014,838-845","journal-title":"ScienceDirect"},{"key":"ref=6","author":"Wilson M.","year":"2020","unstructured":"Wilson M.; Clomipramine. StatPearls  2020","journal-title":"StatPearls"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"Naranjo C.A.","year":"1981","unstructured":"Naranjo C.A.; Busto U.; Sellers E.M.; Sandor P.; Ruiz I.; Roberts E.A.; Janecek E.; Domecq C.; Greenblatt D.J.; A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther  1981,30(2),239-245","journal-title":"Clin Pharmacol Ther"},{"year":"2024","key":"ref=8","unstructured":"The use of the WHO-UMC system for standardized case causality assessment.  Available from:  https:\/\/who-umc.org\/media\/164200\/who-umc-causality-assessment_new-logo.pdf2024"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1093\/ajhp\/49.9.2229","volume":"49","author":"Hartwig SC.","year":"1992","unstructured":"Hartwig SC.; Preventability and severity assessment in reporting adverse drug reactions. Am J Health-Syst Pharm  1992,49(9),2229-2232","journal-title":"Am J Health-Syst Pharm"},{"key":"ref=10","first-page":"538","volume":"27","author":"Schumock GT.","year":"1992","unstructured":"Schumock GT.; Focusing on the preventability of adverse drug reactions. Hosp Pharm  1992,27(6),538","journal-title":"Hosp Pharm"},{"year":"2019","key":"ref=11","unstructured":"Medication safety in polypharmacy.  Available from:  https:\/\/www.who.int\/docs\/default-source\/patient-safety\/who-uhc-sds-2019-11-eng.pdf2019"},{"key":"ref=12","author":"Gardner DM.","year":"2019","unstructured":"Gardner DM.;  Antipsychotic side effects and monitoring implications  2019","journal-title":"Antipsychotic side effects and monitoring implications"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1001\/archpsyc.1990.01810220042005","volume":"47","author":"Pigott T.A.","year":"1990","unstructured":"Pigott T.A.; Pato M.T.; Bernstein S.E.; Grover G.N.; Hill J.L.; Tolliver T.J.; Murphy D.L.; Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. Arch Gen Psychiatry  1990,47(10),926-932","journal-title":"Arch Gen Psychiatry"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748863337946250101110356","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/238948\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748863337946250101110356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T10:01:22Z","timestamp":1764151282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/238948\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115748863337946250101110356","relation":{},"ISSN":["1574-8863"],"issn-type":[{"type":"print","value":"1574-8863"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}